🇺🇸 Empagliflozin 25mg in United States

188 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Urinary Tract Infection — 37 reports (19.68%)
  2. Pollakiuria — 32 reports (17.02%)
  3. Rash — 21 reports (11.17%)
  4. Diabetic Ketoacidosis — 20 reports (10.64%)
  5. Acute Kidney Injury — 16 reports (8.51%)
  6. Nausea — 15 reports (7.98%)
  7. Diarrhoea — 13 reports (6.91%)
  8. Vomiting — 13 reports (6.91%)
  9. Dizziness — 12 reports (6.38%)
  10. Blood Creatinine Increased — 9 reports (4.79%)

Source database →

Empagliflozin 25mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Empagliflozin 25mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Empagliflozin 25mg in United States?

Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.